SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript Summary
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript Summary
Reported a moderate decline in total revenue from $16.3 million in Q3 2023 to $15.9 million in Q3 2024, despite a substantial increase in analysis volumes.The following is a summary of the SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript:
以下是SOPHiA GENETICS SA (SOPH) 2024年第三季度業績會議呼叫成績單摘要:
Financial Performance:
財務表現:
SOPHiA GENETICS reported a year-over-year improvement in cash burn by 39%.
Clinical volume grew 17% year-over-year, ex-COVID influences.
Reported a moderate decline in total revenue from $16.3 million in Q3 2023 to $15.9 million in Q3 2024, despite a substantial increase in analysis volumes.
Achieved an adjusted gross margin of 73.1% and a reduction in adjusted operating loss by 10% year-over-year.
SOPHiA GENETICS報告現金流燃燒同比改善39%。
臨床成交量同比增長17%，不受COVID影響。
報告總營業收入從2023年第三季度的1630萬美元下降至2024年第三季度的1590萬美元，儘管分析量大幅增加。
實現73.1%的調整毛利率，並同比減少10%的調整運營虧損。
Business Progress:
業務進展:
Significant uptake in MSK-ACCESS powered by SOPHiA DDM, with 18 customers globally adopting the application.
Announced leadership changes, positioning for future growth, including Ross Muken's promotion to company President and the appointment of George Cardoza as CFO.
Marked progress in both new and existing genomic customer bases, reaching 462 core genomic customers as of Q3 2024.
Driving new customer adoption and enhancing operational efficiencies.
MSk-ACCESS取得顯著增長，由SOPHiA DDm支持，全球有18家客戶採用該應用程序。
宣佈領導層變動，爲未來增長定位，包括將羅斯·穆肯晉升爲公司總裁，並任命喬治·卡多扎爲首席財務官。
在新基因組客戶群和現有客戶群方面取得顯著進展，截至2024年Q3，核心基因組客戶數量達到462位。
推動新客戶採用並提升運營效率。
Opportunities:
機會：
Expansion of MSK-ACCESS and the introduction of MSK-IMPACT powered by SOPHiA DDM for liquid biopsy and solid tumor testing respectively show strong potential, particularly as these services enable decentralized testing which could lower costs and improve data control for medical institutions.
MSk-ACCESS的擴展和由SOPHiA DDm提供支持的MSk-IMPACt的推出，分別用於液體活檢和實體腫瘤檢測，展現出強大潛力，特別是這些服務能夠實現分散式測試，有望降低成本並提升醫療機構的數據控制能力。
Risks:
風險：
Ongoing economic pressures continue to impact biopharma revenue, which experienced a significant downturn in Q3 2024.
Revenue growth is challenged by macroeconomic factors, affecting customer spending in biopharma sectors, which could influence future financial improvements and market expansions.
持續的經濟壓力繼續影響生物製藥收入，在2024年Q3經歷了顯著下滑。
收入增長受制於宏觀經濟因素，影響生物製藥領域客戶支出，這可能會影響未來的財務改善和市場拓展。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
